Stocks · News reference

Argus Research Upgrades Moderna to Buy, Announces $180 Price Target

Aug 28, 2026, 11:50 AMBenzinga Newsdesk

Argus Research analyst John Eade upgrades Moderna (NASDAQ:MRNA) from Hold to Buy and announces $180 price target.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 28, 2026, 4:43 PMBenzinga Newsdesk
World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency
https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidemic-of-ebola-bundibugyo-virus-disease-in-the-democratic-republic-of-the-congo---meeting-report
Read original at benzinga
CODX EBS GILD GOVX INO
BenzingaAug 28, 2026, 4:16 PMAvi Kapoor
This Moderna Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday
Wall Street analysts upgraded Moderna Inc and Evolution Petroleum Corp, and raised Enbridge's price target. Check out analysts' views on MRNA stock.
Read original at benzinga
ENB EPM MRNA TSX:ENB
BenzingaAug 28, 2026, 1:21 PMBenzinga Newsdesk
Moderna shares are trading lower after the company announced the pricing of its upsized $2.6 billion offering of Convertible Senior Notes.
Read original at benzinga
MRNA
BenzingaAug 28, 2026, 1:11 PMHenry Khederian
Moderna Stock Falls Friday: What's Going On?
Shares of Moderna are trading lower Friday morning after the company announced official terms for a major private debt offering.
Read original at benzinga
MRNA